Are GlaxoSmithKline plc shares a bargain after FY2017 results?

GlaxoSmithKline plc (LON: GSK) currently yields 6.1% and trades on a P/E of 11.8. Does that make the shares a ‘buy’?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 giant GlaxoSmithKline (LSE: GSK) reported full-year results for FY2017 yesterday. Let’s take a closer look at the results and examine the investment case for the healthcare giant. Are the shares a bargain at current levels?

FY2017 results

GSK’s revenue for the period increased 8% (3% at constant currency) to £30.2bn. This was slightly ahead of analysts’ estimates. Sales grew across all three divisions, with the Vaccines division putting in the strongest performance with growth of 12% (6% constant currency).

Adjusted earnings per share came in at 111.8p, growth of 11% (4% constant currency) and the full-year dividend was maintained at 80p per share. CEO Emma Walmsley described the results as “encouraging.”

Investment case

I can see both a bull case and a bear case for buying Glaxo shares right now.

On the bull side, the shares look cheap, and the dividend yield is high. GSK has slumped from above 1,700p in June last year to 1,320p today. That leaves the stock trading on a trailing P/E ratio of just 11.8. Furthermore, the dividend yield looks compelling, at 6.1%. When you consider that it’s hard to get more than 1% per year from a savings account, a yield of over 6% is tempting.

Also, there’s the world’s ageing population to keep in mind. It’s something I wrote about here recently. The global population is getting older. As a result, demand for healthcare products should remain buoyant over the long term. Glaxo is looking to improve its pharmaceuticals business and strengthen its pipeline, and in the long run, should be able to capitalise on this theme.

On the bear side, there are several issues that investors need to be aware of.

In the near term, there are concerns over profitability. Much of this is based around the timing and impact of possible generic competition to GSK’s asthma drug Advair.

Glaxo yesterday advised that in the event of no competition in the US this year, adjusted earnings should be between 4% to 7% higher at constant currency. However, in the event that a generic competitor to Advair is introduced mid-year, adjusted earnings could fall 3% at constant currency. Both scenarios reflect the benefit of the recent US tax reform.

Dividend prospects 

Many investors are also concerned about the dividend. Yesterday, the company advised that shareholders should continue to expect a payout of 80p for 2018. It also said that it recognises the importance of dividends to shareholders.

However, the healthcare giant advised that the dividend will not be increased until free cash flow cover reaches 1.25-1.50 times. Given that free cash flow for 2017 was £3.4bn and the dividend cost the company £3.9bn (a ratio of 0.87), dividend growth looks some way off. Furthermore, a potential consumer health acquisition, such as that of Pfizer, could put a strain on Glaxo’s ability to pay its dividend going forward.

Weighing up both sides, it’s hard to call the investment case for Glaxo right now. From a pure income-investing perspective, there are better dividend stocks out there, in my view. However, from a long-term, tuck-away-for-the-future angle, GSK could have potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How much would I need to invest in income shares to earn £300 a month?

What kind of lump sum would be required to earn £300 a month by taking advantage of some of the…

Read more »

Investing For Beginners

Up 31% in a month, could this FTSE 250 stock be getting bought out?

Jon Smith takes a look at speculation that's pushing the share price of a FTSE 250 share higher and considers…

Read more »

Investing Articles

Here’s how I’d follow Warren Buffett to start building passive income in 2025

Ben McPoland highlights one FTSE 250 firm with a strong competitive edge that he thinks can continue rewarding investors with…

Read more »

Investing Articles

Burberry shares: undervalued FTSE gems that are ready to rocket?

Burberry shares soared at the beginning of the week as the takeover rumour mill went into overdrive. Is Paul Summers…

Read more »

US Stock

Here are the latest share price forecasts for S&P 500 giant Amazon

Amazon has generated monster gains for investors over the last decade. And Wall Street analysts believe the S&P 500 stock…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »